Five things for pharma marketers to know: Tuesday, January 5, 2016
1. The FDA has granted Gilead Sciences's hepatitis C combo of sofosbuvir and velpatasvir Breakthrough Therapy designation for treatment in all genotypes of the virus. The government agency set a decision date of June 28 to review the experimental drug.
2. Baxalta announced it will pay up to $1.6 billion for the right to co-develop six potential oncology treatments from Danish biotech Symphogen. Baxalta is currently in negotiations to sell its company to Shire. Baxalta will dole out $175 million to Symphogen upfront; the most advanced drugs in the deal are expected to enter human clinical trials in 2017. (WSJ)
3. A Google and Bill Gates-backed drugmaker, Editas Medicine, filed its initial public offering. The company boasts a new technology that can edit flaws in people's genes. (Bloomberg)
4. Novartis agreed to settle a class-action lawsuit that alleged that the drugmaker denied women opportunities and equal pay due to their gender. The suit was filed by employees of its Alcon business unit. The suit also charged that less than 15% of the leadership positions at the drugmaker were filled by women. (Stat)
5. ICYMI: Endo International ended its agreement with Vivus to co-market its erectile dysfunction treatment Stendra. Endo's subsidiary Auxilium inked the deal in 2013; the drugmaker said in the first quarter of 2014 that Stendra had captured 6% of new erectile dysfunction prescriptions. (Philadelphia Business Journal)